Plasma Aβ42 correlates positively with increased body fat in healthy individuals

Journal of Alzheimer's Disease

Volumn 8, Issue 3, 2005, Pages 269-282

  Balakrishnan, Kelvin ^a,c   Verdile, Giuseppe ^a,b   Mehta, Pankaj D ^d   Beilby, John ^c,e   Nolan, David ^f   Galvão, Daniel A ^b   Newton, Robert ^b   Gandy, Samuel E ^g   Martins, Ralph N ^a,b,c  

^a HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^e Western Australian Centre for Pathology and Medical Research   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

AD, Alzheimer's disease; APOE 4, Apolipoprotein E epsilon 4 allele; A , amyloid beta protein; BMI, body mass index; CRP, C reactive protein; FM, Fat Mass; HDL, High density lipoprotein; IL, interleukin; LDL, Low density Lipoprotein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEPTIDE FRAGMENT;

ADULT; ADULTHOOD; ARTICLE; BLOOD LEVEL; BODY FAT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LONGITUDINAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; ADIPOSE TISSUE; ALZHEIMER DISEASE; BLOOD; HEALTH STATUS; METABOLISM; MIDDLE AGED;

ADIPOSE TISSUE; ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HEALTH STATUS; HUMANS; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RISK FACTORS;

EID: 33644592540     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2005-8305     Document Type: Article

References (79)

1. S. Bodovitz and W.L. Klein, Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein, J Biol Chem 271 (1996), 4436-4440.
2. E. Bonora, C. Coscelli and U. Butturini, Secretion and hepatic extraction of insulin in nondiabetic, obese, aged subjects, J Am Geriatr Soc 31 (1983), 333-337.
3. E. Bonora, I. Zavaroni, C. Coscelli and U. Butturini, Decreased hepatic insulin extraction in subjects with mild glucose intolerance, Metabolism 32 (1983), 438-446.
4. D. Bunout, C. Munoz, M. Lopez, M.P. de la Maza, L. Schlesinger, S. Hirsch and M. Pettermann, Interleukin 1 and tumor necrosis factor in obese alcoholics compared with normal-weight patients, Am J Clin Nutr 63 (1996), 373-376.
5. J.D. Buxbaum, M. Oishi, H.I. Chen, R. Pinkas-Kramarski, E.A. Jaffe, S.E. Gandy and P. Greengard, Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor, Proc Natl Acad Sci USA 89 (1992), 10075-10078.
6. R. Cacabelos, L. Fernandez-Novoa, V. Lombardi, L. Corzo, V. Pichel and Y. Kubota, Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications, Neurol Res 25 (2003), 567-580.
7. A.J. Cameron, T.A. Welborn, P.Z. Zimmet, D.W. Dunstan, N. Owen, J. Salmon, M. Dalton, D. Jolley and J.E. Shaw, Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab), Med J Aust 178 (2003), 427-432.
8. C.C. Chao, S. Hu, W.H. Frey, 2nd, T.A. Ala, W.W. Tourtellotte and P.K. Peterson, Transforming growth factor beta in Alzheimer's disease, Clin Diagn Lab Immunol 1 (1994), 109-110.
9. G.M. Cole, W. Beech, S.A. Frautschy, J. Sigel, C. Glasgow and M.D. Ard, Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro, J Neurosci Res 57 (1999), 504-520.
10. D.G. Cook, M.A. Mendall, P.H. Whincup, I.M. Carey, L. Ballam, J.E. Morris, G.J. Miller and D.P. Strachan, C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors, Atherosclerosis 149 (2000), 139-150.
11. P. Dandona, R. Weinstock, K. Thusu, E. Abdel-Rahman, A. Aljada and T. Wadden, Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss, J Clin Endocrinol Metab 83 (1998), 2907-2910.
12. R. Elosua, S. Demissie, L.A. Cupples, J.B. Meigs, P.W. Wilson, E.J. Schaefer, D. Corella and J.M. Ordovas, Obesity modulates the association among APOE genotype, insulin, and glucose in men, Obes Res 11 (2003), 1502-1508.
13. Z.S. Farhangrazi, H. Ying, G. Bu, L.L. Dugan, A.M. Fagan, D.W. Choi and D.M. Holtzman, High density lipoprotein decreases beta-amyloid toxicity in cortical cell culture, Neuroreport 8 (1997), 1127-1130.
14. Expert panel on the identification, evaluation and treatment of overweight and obesity in adults, Clinical guidelines on the identification, Evaluation, and treatment of overweight and obesity in adults, Am J Clin Nutr 68 (1998), 899-917.
15. Expert panel on the identification, evaluation and treatment of overweight and obesity in adults, Executive summary of clinical guidelines on the identifiaction, evaluation and treatment of overweight and obesity in adults, Arch Intern Med 158 (1998), 1855-1867.
16. W. Farris, S. Mansourian, Y. Chang, L. Lindsley, E.A. Eckman, M.P. Frosch, C.B. Eckman, R.E. Tanzi, D.J. Selkoe and S. Guenette, Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo, Proc Natl Acad Sci USA 100 (2003), 4162-4167.
17. A. Festa, R. D'Agostino, Jr., G. Howard, L. Mykkanen, R.P. Tracy and S.M. Haffner, Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS), Circulation 102 (2000), 42-47.
18. H. Fillit, W.H. Ding, L. Buee, J. Kalman, L. Altstiel, B. Lawlor and G. Wolf-Klein, Elevated circulating tumor necrosis factor levels in Alzheimer's disease, Neurosci Lett 129 (1991), 318-320.
19. W.T. Friedewald, R.I. Levy and D.S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of prearative ultracentrifuge, Clin Chem 18 (1972), 499-502.
20. L. Gasparini, G.K. Gouras, R. Wang, R.S. Gross, M.F. Beal, P. Greengard and H. Xu, Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling, J Neurosci 21 (2001), 2561-2570.
21. H. Ghanim, A. Aljada, D. Hofmeyer, T. Syed, P. Mohanty and P. Dandona, Circulating mononuclear cells in the obese are in a proinflammatory state, Circulation 110 (2004), 1564-1571.
22. W.S. Griffin, L.C. Stanley, C. Ling, L. White, V. MacLeod, L.J. Perrot, C.L. White, 3rd. and C. Araoz, Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease, Proc Natl Acad Sci USA 86 (1989), 7611-7615.
23. D. Gustafson, E. Rothenberg, K. Blennow, B. Steen and I. Skoog, An 18-year follow-up of overweight and risk of Alzheimer disease, Arch Intern Med 163 (2003), 1524-1528.
24. S.M. Haffner, Insulin resistance, inflammation, and the prediabetic state, Am J Cardiol 92 (2003), 18J-26J.
25. F. Haverkate, S.G. Thompson, S.D. Pyke, J.R. Gallimore and M.B. Pepys, Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group, Lancet 349 (1997), 462-466.
26. J.E. Hixson and D.T. Vernier, Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI, J Lipid Res 3 (1990), 545-548.
27. A. Hofman, A. Ott, M.M. Breteler, M.L. Bots, A.J. Slooter, F. van Harskamp, C.N. van Duijn, C. Van Broeckhoven and D.E. Grobbee, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, Lancet 349 (1997), 151-154.
28. M. Hull, M. Berger, B. Volk and J. Bauer, Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques, Ann N Y Acad Sci 777 (1996), 205-212.
29. B.A. in t' Veld, A. Ruitenberg, A. Hofman, L.J. Launer, C.M. van Duijn, T. Stijnen, M.M. Breteler and B.H. Stricker, Non-steroidal antiinflammatory drugs and the risk of Alzheimer's disease, N Engl J Med 345 (2001), 1515-1521.
30. A. Jager, V.W. van Hinsbergh, P.J. Kostense, J.J. Emeis, J.S. Yudkin, G. Nijpels, J.M. Dekker, R.J. Heine, L.M. Bouter and C.D. Stehouwer, von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study, Arterioscler Thromb Vasc Biol 19 (1999), 3071-3078.
31. A. Jellema, J. Plat and R.P. Mensink, Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state, Eur J Clin Invest 34 (2004), 766-773.
32. E.P. Jonhson, American College of Sports Medicine Lippincott Williams & Wilkins, Philadelphia, 2000.
33. L. Khaodhiar, P.R. Ling, G.L. Blackburn and B.R. Bistrian, Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity, JPEN J Parenter Enteral Nutr 28 (2004), 410-415.
34. W. Koenig, M. Sund, M. Frohlich, H.G. Fischer, H. Lowel, A. Doring, W.L. Hutchinson and M.B. Pepys, C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992, Circulation 99 (1999), 237-242.
35. R.M. Krauss, Lipids and lipoproteins in patients with type 2 diabetes, Diabetes Care 27 (2004), 1496-1504.
36. Y.M. Kuo, M.R. Emmerling, C.L. Bisgaier, A.D. Essenburg, H.C. Lampert, D. Drumm and A.E. Roher, Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels, Biochem Biophys Res Commun 252 (1998), 711-715.
37. I.V. Kurochkin, Insulin-degrading enzyme: embarking on amyloid destruction, Trends Biochem Sci 26 (2001), 421-425.
38. I.V. Kurochkin and S. Goto, Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme, FEBS Lett 345 (1994), 33-37.
39. J. Kuusisto, K. Koivisto, L. Mykkanen, E.L. Helkala, M. Vanhanen, T. Hanninen, K. Kervinen, Y.A. Kesaniemi, P.J. Riekkinen and M. Laakso, Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study, Bmj 315 (1997), 1045-1049.
40. C.L. Lafortuna, F. Agosti, P.G. Marinone, N. Marazzi and A. Sartorio, The relationship between body composition and muscle power output in men and women with obesity, J Endocrinol Invest 27 (2004), 854-861.
41. S.M. Laws, R.M. Clarnette, K. Taddei, G. Martins, A. Paton, J. Hallmayer, O.P. Almeida, D.M. Groth, S.E. Gandy, H. Forstl, R.N. Martins, D. Yang, C. Fisher, R. Clarnette, R. Barnetson, R. Maller, W.S. Brooks, S. Whyte, G.A. Nicholson, C.L. Masters and G.A. Broe, APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss No association of presenilin-1 intronic polymorphism and Alzheimer's disease in Australia, Mol Psychiatry 7 (2002), 768-775.
42. S.M. Laws, E. Hone, S. Gandy and R.N. Martins, Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription, J Neurochem 84 (2003), 1215-1236.
43. Y.F. Liao, B.J. Wang, H.T. Cheng, L.H. Kuo and M.S. Wolfe, Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway, J Biol Chem 279 (2004), 49523-49532.
44. J.A. Luchsinger, M.X. Tang, S. Shea and R. Mayeux, Caloric intake and the risk of Alzheimer disease, Arch Neurol 59 (2002), 1258-1263.
45. J.A. Luchsinger, M.X. Tang, S. Shea and R. Mayeux, Hyperinsulinemia and risk of Alzheimer disease, Neurology 63 (2004), 1187-1192.
46. R. Mayeux, L.S. Honig, M.X. Tang, J. Manly, Y. Stern, N. Schupf and P.D. Mehta, Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk, Neurology 61 (2003), 1185-1190.
47. R. Mayeux, M.X. Tang, D.M. Jacobs, J. Manly, K. Bell, C. Merchant, S.A. Small, Y. Stern, H.M. Wisniewski and P.D. Mehta, Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease, Ann Neurol 46 (1999), 412-416.
48. P.L. McGeer, M. Schulzer and E.G. McGeer, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies, Neurology 47 (1996), 425-432.
49. P.D. Mehta, A.J. Dalton, S.P. Mehta, K.S. Kim, E.A. Sersen and H.M. Wisniewski, Increased plasma amyloid beta protein 1-42 levels in Down syndrome, Neurosci Lett 241 (1998) 13-16.
50. P.D. Mehta, T. Pirttila, S.P. Mehta, E.A. Sersen, P.S. Aisen and H.M. Wisniewski, Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease, Arch Neurol 57 (2000), 100-105.
51. A. Merched, Y. Xia, S. Visvikis, J.M. Serot and G. Siest, Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease, Neurobiol Aging 21 (2000), 27-30.
52. A. Merched, Y. Xia, S. Visvikis, J.M. Serot, G. Siest, A.R. Koudinov, N.V. Koudinova, T.T. Berezov and Y.D. Ivanov, Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease HDL phospholipid: a natural inhibitor of Alzheimer's amyloid beta-fibrillogenesis? Neurobiol Aging 21 (2000), 27-30.
53. M. Mulder and D. Terwel, Possible link between lipid metabolism and cerebral amyloid angiopathy in Alzheimer's disease: A role for high-density lipoproteins? Haemostasis 28 (1998), 174-194.
54. J. Naslund, V. Haroutunian, R. Mohs, K.L. Davis, P. Davies, P. Greengard and J.D. Buxbaum, Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline, Jama 283 (2000), 1571-1577.
55. National Heart, Lung and Blood Institute, Clinical guidelines on the indentification, evaluation and treatment of Overweight and obesity in adults: The Evidence report. Bethesda, Md: National Institutes of Health, 1998.
56. I.L. Notkola, R. Sulkava, J. Pekkanen, T. Erkinjuntti, C. Ehnholm, P. Kivinen, J. Tuomilehto and A. Nissinen, Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease, Neuroepidemiology 17 (1998), 14-20.
57. O.F. Olesen and L. Dago, High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils, Biochem Biophys Res Commun 270 (2000), 62-66.
58. A. Ott, R.P. Stolk, A. Hofman, F. van Harskamp, D.E. Grobbee and M.M. Breteler, Association of diabetes mellitus and dementia: the Rotterdam Study, Diabetologia 39 (1996), 1392-1397.
59. A. Papassotiropoulos, C. Hock and R.M. Nitsch, Genetics of interleukin 6: implications for Alzheimer's disease, Neurobiol Aging 22 (2001), 863-871.
60. R. Peila, B.L. Rodriguez and L.J. Launer, Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study, Diabetes 51 (2002), 1256-1262.
61. E.S. Rawson, P.S. Freedson, S.K. Osganian, C.E. Matthews, G. Reed and I.S. Ockene, Body mass index, but not physical activity, is associated with C-reactive protein, Med Sci Sports Exerc 35 (2003), 1160-1166.
62. L.M. Refolo, B. Malester, J. LaFrancois, T. Bryant-Thomas, R. Wang, G.S. Tint, K. Sambamurti, K. Duff and M.A. Pappolla, Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model, Neurobiol Dis 7 (2000), 321-331.
63. P.M. Ridker, High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit, Am Heart J 148 (2004), S19-26.
64. G. Sun, C.R. French, G.R. Martin, B. Younghusband, R.C. Green, Y.G. Xie, M. Mathews, J.R. Barron, D.G. Fitzpatrick, W. Gulliver and H. Zhang, Comparison of multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for assessment of percentage body fat in a large, healthy population, Am J Clin Nutr 81 (2005), 74-78.
65. K. Taddei, D. Yang, C. Fisher, R. Clarnette, J. Hallmayer, R. Barnetson, R. Maller, W.S. Brooks, S. Whyte, G.A. Nicholson, C.L. Masters, G.A. Broe, S.E. Gandy and R.N. Martins, No association of presenilin-1 intronic polymorphism and Alzheimer's disease in Australia, Neurosci Lett 246 (1998), 178-180.
66. K. Tamakoshi, H. Yatsuya, T. Kondo, M. Ishikawa, H. Zhang, C. Murata, R. Otsuka, T. Mabuchi, Y. Hori, S. Zhu, T. Yoshida and H. Toyoshima, Long-term body weight variability is associated with elevated C-reactive protein independent of current body mass index among Japanese men, Int J Obes Relat Metab Disord 27 (2003), 1059-1065.
67. A. Tamaoka, T. Fukushima, N. Sawamura, K. Ishikawa, E. Oguni, Y. Komatsuzaki and S. Shoji, Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease, J Neurol Sci 141 (1996), 65-68.
68. E. Tarkowski, R. Issa, M. Sjogren, A. Wallin, K. Blennow, A. Tarkowski and P. Kumar, Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia, Neurobiol Aging 23 (2002), 237-243.
69. J.L. Torres and P.M. Ridker, Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events, Curr Opin Cardiol 18 (2003), 471-478.
70. R.P. Tracy, R.N. Lemaitre, B.M. Psaty, D.G. Ives, R.W. Evans, M. Cushman, E.N. Meilahn and L.H. Kuller, Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project, Arterioscler Thromb Vasc Biol 17 (1997), 1121-1127.
71. V. Trischitta, A. Brunetti, A. Chiavetta, L. Benzi, V. Papa and R. Vigneri, Defects in insulin-receptor internalization and processing in monocytes of obese subjects and obese NIDDM patients, Diabetes 38 (1989), 1579-1584.
72. C.M. van Duijn, A. Hofman and L. Nagelkerken, Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease, Neurosci Lett 108 (1990), 350-354.
73. G. Verdile, S. Fuller, C.S. Atwood, S.M. Laws, S.E. Gandy and R.N. Martins, The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol Res 50 (2004), 397-409.
74. A.N. Vgontzas, E.O. Bixler and G.P. Chrousos, Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance, J Intern Med 254 (2003), 32-44.
75. G.S. Watson, E.R. Peskind, S. Asthana, K. Purganan, C. Wait, D. Chapman, M.W. Schwartz, S. Plymate and S. Craft, Insulin increases CSF Abeta42 levels in normal older adults, Neurology 60 (2003), 1899-1903.
76. J.D. Weaver, M.H. Huang, M. Albert, T. Harris, J.W. Rowe and T.E. Seeman, Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 59 (2002), 371-378.
77. P.R. Wenham, W.H. Price and G. Blandell, Apolipoprotein E genotyping by one-stage PCR, Lancet 337 (1991), 1158-1159.
78. P.P. Zandi and J.C. Breitner, Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence, Neurobiol Aging 22 (2001), 811-817.
79. H. Zetterberg, N. Andreasen and K. Blennow, Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease, Neurosci Lett 367 (2004), 194-196.